Agilent Technologies
VC Fund
Santa Clara, United States
Agilent Technologies is a VC fund in Santa Clara focused on Biotechnology and Health Care. Agilent provides laboratory solutions to meet the needs of analytical scientists and clinical researchers worldwide. Agilent works closely with customers to help address global trends that impact human health and the environment and to anticipate future scientific needs. Agilent's solutions improve the efficiency of the entire laboratory, fromsample prep to data interpretation and management.
- Total investments:
- 41
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Agilent Technologies invests in
BiotechnologyHealth CareGeneticsManufacturingWireless
Stages Agilent Technologies invests in
Series BSeries ASeries CVenture - Series UnknownFunding Round
Countries Agilent Technologies invests in
United StatesUnited KingdomCanadaFranceGermany
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joe Guiles
|
|||
Paul Beresford
|
|||
Sue Rataj
|
|||
Ailee Grumbine
|
|||
Amanda Haas
|
Investment Focus
Industry
- Biotechnology 16 (39%)
- Health Care 10 (24%)
- Genetics 5 (12%)
- Manufacturing 5 (12%)
- Wireless 4 (10%)
Stage
- Series B 13 (32%)
- Series A 7 (17%)
- Series C 7 (17%)
- Venture - Series Unknown 4 (10%)
- Funding Round 2 (5%)
Country
- United States 23 (56%)
- United Kingdom 2 (5%)
- Canada 1 (2%)
- France 1 (2%)
- Germany 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Joe Guiles
Head of Development
|
Head of Development | Total investments: 0 | Find email | |
|
Paul Beresford
VP and GM of CDx
|
VP and GM of CDx | Total investments: 0 | Find email | |
|
Sue Rataj
Member of Board of Directors
|
Member of Board of Directors | Total investments: 0 | Find email | |
|
Ailee Grumbine
Product Marketing Engineer
|
Product Marketing Engineer | Total investments: 0 | Find email | |
|
Amanda Haas
Business Development Manager & Gene Editing Therapeutics
|
Business Development Manager & Gene Editing Therapeutics | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Halo X Ray Technologies
|
HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range ofapplication areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market. | Corporate Round / Jul 20, 2026 | |
|
Halo X Ray Technologies
|
HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range ofapplication areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market. | Venture - Series Unknown / Jul 20, 2026 | |
Mission Bio
|
Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas includeoncology blood cancers, solid tumors, and genome editing validation. | Venture - Series Unknown / Aug 05, 2025 | |
RareCyte
|
RareCyte is a provider of precision biology solutions that delivers platforms and services in both spatial biology and liquid biopsy. It offers tissue-based imaging tools under the Orion Spatial Biology suite, including imaging instruments and panels enabling multiplexed biomarker analysis in a single scan, and supplies rare cell analysisinstruments and consumables such as the CyteFinder II imaging systems, CytePicker module, AccuCyte sample preparation, and RarePlex panel kits for circulating tumor cell (CTC) detection and characterization. Additionally, RareCyte extends its offering with precision biology services encompassing custom assay development, clinical trial sample testing, and data analysis. | $20M / Venture - Series Unknown / Jun 27, 2024 | |
Elegen
|
Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances. The company was founded in 2017 and led by Dr. Matthew Hill. | $35M / Series B / May 14, 2024 | |
Biofidelity
|
Biofidelity developed a revolutionary molecular diagnostic assay that enables the rapid detection of target DNA sequences. Biofidelity’s mission is to improve and extend patients’ lives by enabling early detection of disease and better targeting of treatments with applications spanning oncology, prenatal testing, infectious disease, and organtransplant monitoring.Biofidelity was founded in 2019 and is headquartered of Cambridge, England. | $24M / Venture - Series Unknown / Apr 03, 2024 | |
|
Halo X Ray Technologies
|
HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range ofapplication areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market. | $2.5M / Series A / Sep 06, 2023 | |
Halo Labs
|
Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics.Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced ResearchProjects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.The company was founded in 2011 and headquartered in Pennsylvania, United States. | $7M / Series C / Jul 08, 2022 | |
Molecular Assemblies
|
Molecular Assemblies is a San Diego-based company developing a revolutionary, enzymatic DNA synthesis technology capable of powering new products in industrial synthetic biology, personalized therapeutics, precision diagnostics, and eventually information storage, nanotechnology and more. Inspired by nature, the company’s proprietary DNA synthesismethod is designed to produce long, high quality, sequence-specific DNA reliably, affordably and sustainably. With a highly experienced executive and scientific team and an expansive intellectual property portfolio, Molecular Assemblies has attracted investments from Agilent Technologies, Cavendish Impact Capital Fund, Data Collective Venture Capital, Eleven Two Capital, Genomics Investment Syndicate, Keshif Ventures, Newport Holdings, LP, and Alexandria Venture Investments. | $25.8M / Series B / Mar 15, 2022 | |
Arima Genomics
|
Arima Genomics is a biotechnology company that aims to accelerate the understanding of genome sequence and structure. | $7M / Series B / Mar 15, 2022 | |
| See all 41 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Hardware Investors
40,144 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Health Care VC Funds
32,370 investors
FAQ
What does Agilent Technologies invest in?
Agilent Technologies invests primarily in Biotechnology, Health Care and Genetics startups, most often at Series B and Series A stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Agilent Technologies?
Public channels for Agilent Technologies include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Agilent Technologies?
The team at Agilent Technologies includes Joe Guiles (Head of Development), Paul Beresford (VP and GM of CDx) and Sue Rataj (Member of Board of Directors), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
